Allergan’s Botox For Removing Glabellar Lines Yet To Receive SFDA Approval
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline China Investment introduced Allergan-developed Botox into China in October 2006 as a drug for one-sided facial muscle spasms and eyelid twitching. However, the popular wrinkle-removing Botox injection has yet to receive China's State FDA approval for treatment of glabellar lines between eyebrows. GSK officials say Botox for removing glabellar lines is still in clinical trials, but declined to comment on the progress or expected market prospects for the drug in China. On the other hand, botulinum toxin type A produced by local firm Lanzhou Institute of Biological Products has captured the China market. Although it has not been approved for glabellar lines removal, the drug has gained widespread cosmetic use in many domestic plastics institutions. (Click here for more - Chinese Language)
You may also be interested in...
China SFDA Moves Botulinum Toxin Type A Under Toxic Drug Category
SHANGHAI - China's Ministry of Health and State FDA have moved neurotoxin Botox (botulinum toxin type A) under toxic drug control, the two institutions declared in a joint notice July 22
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.